Earnings Summary

Oncocyte Corp’s revenue fell -77.6% since last year same period to $0.46Mn in the Q2 2023. On a quarterly growth basis, Oncocyte Corp has generated 113.04% jump in its revenue since last 3-months.

Oncocyte Corp’s net profit fell -0.4% since last year same period to $-8.33Mn in the Q2 2023. On a quarterly growth basis, Oncocyte Corp has generated 81.47% jump in its net profits since last 3-months.

Oncocyte Corp’s net profit margin fell -348.21% since last year same period to -1799.78% in the Q2 2023. On a quarterly growth basis, Oncocyte Corp has generated -242.05% fall in its net profit margins since last 3-months.

Oncocyte Corp’s earning per share (EPS) estimates for the current quarter stand at -0.1 - a -2.9% fall from last quarter’s estimates.

Oncocyte Corp’s earning per share (EPS) estimates for the current year stand at -0.1.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Oncocyte Corp’s return on assets (ROA) stands at -0.12.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Oncocyte Corp’s return on equity (ROE) stands at -0.24.